LONDON - AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), the UK-based global biopharmaceutical company, has announced the appointment of Iskra Reic as its new Executive Vice President (EVP), International. Reic's vast experience within the company and her recent leadership of the Vaccines and Immune Therapies unit have positioned her to take on this role, overseeing the company's strategy and growth in a diverse range of markets including China, Asia, Eurasia, the Middle East & Africa, Latin America, Australia, and New Zealand.
Reic, who joined AstraZeneca (NASDAQ:AZN) in 2001, has a strong background in leadership across various regions, having previously served as EVP for Europe & Canada. Her tenure at AstraZeneca includes significant contributions to the development and commercialization of the company's pipeline, including COVID-19 and RSV vaccines, and monoclonal antibodies.
Pascal Soriot, CEO of AstraZeneca, praised Reic's international experience and her ability to improve patient access to the company's medicines. He also highlighted her expertise in building partnerships as a key asset for the company's growth in the international markets.
Reic expressed her commitment to advancing AstraZeneca's science and medicine portfolio and emphasized collaboration with partners and stakeholders to enhance patient outcomes globally. She takes over from Leon Wang, who is currently on extended leave amid an investigation in China.
AstraZeneca is a science-led firm specializing in prescription medicines across several therapeutic areas, including Oncology, Rare Diseases, and BioPharmaceuticals. The company's products reach over 125 countries, with a mission to deliver innovative treatments to patients worldwide.
Reic's educational background includes a PhD and an MBA in Business and Leadership from IEDC-Bled School of Management, Slovenia, and a DMD from the Medical (TASE:PMCN) University of Zagreb. She also serves on the Board of Directors for myTomorrows, a health technology company, and is involved in the Partnership for Health System Sustainability and Resilience.
This announcement is based on a press release statement from AstraZeneca and reflects the company's latest executive movement as it continues to expand its international presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.